Pathological transition as the arising mechanism for drug resistance in lung cancer  

作　　者：Yueqing Chen Waiying Yvonne Tang Xinyuan Tong Hongbin Ji 

机构地区：[1]State Key Laboratory of Cell Biology,CAS Center for Excellence on Molecular Cell Science,Innovation Center for Cell Signaling Network,Institute of Biochemistry and Cell Biology,Shanghai Institutes for Biological Sciences,Chinese Academy of Sciences,Shanghai 200031,P.R.China [2]University of Chinese Academy of Sciences,Beijing 100049,P.R.China [3]Sunway Medical Centre,47500 Bandar Sunway,Selangor,Malaysia [4]School of Life Science and Technology,Shanghai Tech University,Shanghai 200120,P.R.China

出　　处：《Cancer Communications》2019年第1期469-481,共13页癌症通讯（英文）

基　　金：This work was supported by the National Basic Research Program of China(Grant No.2017YFA0505501);Strategic Priority Research Program of the Chinese Academy of Sciences(Grant No.XDB19020201);National Natural Science Foundation of China(Grant Nos.81430066,91731314,31621003,81872312,81871875,81802279).

摘　　要：Despite the tremendous efforts for improving therapeutics of lung cancer patients,its prognosis remains disappoint-ing.This can be largely attributed to the lack of comprehensive understanding of drug resistance leading to insuf-ficient development of effective therapeutics in clinic.Based on the current progresses of lung cancer research,we classify drug resistance mechanisms into three different levels:molecular,cellular and pathological level.All these three levels have significantly contributed to the acquisition and evolution of drug resistance in clinic.Our under-standing on drug resistance mechanisms has begun to change the way of clinical practice and improve patient prognosis.In this review,we focus on discussing the pathological changes linking to drug resistance as this has been largely overlooked in the past decades.

关 键 词：Lung cancer Drug resistance Pathological transition 

分 类 号：R73[医药卫生—肿瘤]